CN119487035A - 双官能基化合物及包含所述双官能基化合物的医药组合物及其用于治疗雄激素受体相关疾病的方法 - Google Patents

双官能基化合物及包含所述双官能基化合物的医药组合物及其用于治疗雄激素受体相关疾病的方法 Download PDF

Info

Publication number
CN119487035A
CN119487035A CN202380051072.6A CN202380051072A CN119487035A CN 119487035 A CN119487035 A CN 119487035A CN 202380051072 A CN202380051072 A CN 202380051072A CN 119487035 A CN119487035 A CN 119487035A
Authority
CN
China
Prior art keywords
substituted
group
unsubstituted
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380051072.6A
Other languages
English (en)
Chinese (zh)
Inventor
林助强
陈宏铨
郑沛晴
周志璋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhong Biomedical Co ltd
Original Assignee
Anhong Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anhong Biomedical Co ltd filed Critical Anhong Biomedical Co ltd
Publication of CN119487035A publication Critical patent/CN119487035A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
CN202380051072.6A 2022-06-30 2023-06-29 双官能基化合物及包含所述双官能基化合物的医药组合物及其用于治疗雄激素受体相关疾病的方法 Pending CN119487035A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263357054P 2022-06-30 2022-06-30
US63/357,054 2022-06-30
PCT/CN2023/103576 WO2024002206A1 (en) 2022-06-30 2023-06-29 Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related diseases by using the same

Publications (1)

Publication Number Publication Date
CN119487035A true CN119487035A (zh) 2025-02-18

Family

ID=89383152

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202380051072.6A Pending CN119487035A (zh) 2022-06-30 2023-06-29 双官能基化合物及包含所述双官能基化合物的医药组合物及其用于治疗雄激素受体相关疾病的方法
CN202380051052.9A Pending CN119487034A (zh) 2022-06-30 2023-06-29 双官能基化合物及包含所述双官能基化合物的医药组合物及其用于治疗雄激素受体相关疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202380051052.9A Pending CN119487034A (zh) 2022-06-30 2023-06-29 双官能基化合物及包含所述双官能基化合物的医药组合物及其用于治疗雄激素受体相关疾病的方法

Country Status (11)

Country Link
US (3) US20250197409A1 (https=)
EP (2) EP4547667A1 (https=)
JP (2) JP2025524557A (https=)
KR (2) KR20250027728A (https=)
CN (2) CN119487035A (https=)
AU (2) AU2023300784A1 (https=)
CA (2) CA3259653A1 (https=)
IL (1) IL318001A (https=)
MX (2) MX2024015832A (https=)
TW (2) TWI893405B (https=)
WO (3) WO2024002289A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118955474A (zh) * 2024-07-29 2024-11-15 浙江爱索拓标记医药科技有限公司 一种放射性同位素碳-14标记的巴德卡鲁胺及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2738833C9 (ru) * 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
CA2988414C (en) * 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
IL312367A (en) * 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
EP3658548A1 (en) * 2017-07-28 2020-06-03 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
IL302595A (en) * 2018-04-13 2023-07-01 Arvinas Operations Inc Servalon ligands and bifunctional compounds containing them
WO2020211822A1 (zh) * 2019-04-18 2020-10-22 成都海创药业有限公司 一类靶向降解雄激素受体的双功能嵌合体杂环化合物及其用途
CN114829342A (zh) * 2019-12-23 2022-07-29 上海济煜医药科技有限公司 一种蛋白降解剂化合物的制备方法和应用
WO2021143816A1 (zh) * 2020-01-16 2021-07-22 江苏恒瑞医药股份有限公司 稠合酰亚胺类衍生物、其制备方法及其在医药上的应用
WO2021231927A1 (en) * 2020-05-14 2021-11-18 The Regents Of The University Of Michigan Androgen receptor protein degraders with a tricyclic cereblon ligand
WO2022011205A1 (en) * 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Androgen receptor protein degraders
KR20220014952A (ko) * 2020-07-29 2022-02-08 한국화학연구원 안드로겐 수용체의 저해 또는 분해용 화합물 및 이들의 의약 용도
CN114163444B (zh) * 2020-09-11 2023-07-14 江苏恒瑞医药股份有限公司 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
JP2023547084A (ja) * 2020-10-21 2023-11-09 アルビナス・オペレーションズ・インコーポレイテッド アンドロゲン受容体タンパク質の標的分解のための化合物および方法

Also Published As

Publication number Publication date
JP2025524557A (ja) 2025-07-30
AU2023296682A1 (en) 2025-01-02
IL318001A (en) 2025-02-01
EP4547668A1 (en) 2025-05-07
MX2024015833A (es) 2025-04-02
TWI893404B (zh) 2025-08-11
US20240018149A1 (en) 2024-01-18
EP4547667A1 (en) 2025-05-07
KR20250028370A (ko) 2025-02-28
CA3259653A1 (en) 2024-01-04
TW202404976A (zh) 2024-02-01
US20240336620A1 (en) 2024-10-10
WO2024002205A1 (en) 2024-01-04
JP2025520909A (ja) 2025-07-03
WO2024002206A1 (en) 2024-01-04
TWI893405B (zh) 2025-08-11
US20250197409A1 (en) 2025-06-19
MX2024015832A (es) 2025-04-02
CN119487034A (zh) 2025-02-18
TW202408505A (zh) 2024-03-01
WO2024002289A1 (en) 2024-01-04
AU2023300784A1 (en) 2025-01-02
KR20250027728A (ko) 2025-02-27
CA3259652A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
JP7707310B2 (ja) 置換されたピリダジンフェノール系誘導体
JP2023539584A (ja) 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
KR102462288B1 (ko) 스피로-락탐 및 비스-스피로-락탐 nmda 수용체 조정제 및 그의 용도
EP3541804B1 (en) Cycloalkyl substituted triazole compounds as agonists of the apj receptor
JP2021512109A (ja) スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
JP2023130361A (ja) セミカルバジド感受性アミンオキシダーゼ阻害剤の調製及びその応用
EA003856B1 (ru) Антипикорнавирусные композиции, их получение и применение
WO2012022121A1 (zh) 作为盐皮质激素受体拮抗剂的并环类化合物
JP2025523440A (ja) 芳香族化合物およびその製造方法ならびにエストロゲン受容体分解剤の製造における使用
ES2653931T3 (es) Tiazolo y oxazolo-pirimidinonas condensadas
CN119487035A (zh) 双官能基化合物及包含所述双官能基化合物的医药组合物及其用于治疗雄激素受体相关疾病的方法
JP7481689B2 (ja) Ｅｅｄ阻害剤、その製造方法およびその使用
KR20250056970A (ko) 일련의 질소 함유 가교 헤테로고리 화합물 및 이의 제조방법
JP2024522633A (ja) ベンゾオキサジノン誘導体
NL2031175B1 (en) Dhcr24 inhibitory compounds
HK40117251A (zh) 双官能基化合物及包含所述双官能基化合物的医药组合物及其用於治疗雄激素受体相关疾病的方法
CA3251670A1 (en) KLF2 INDUCERS AND THEIR METHODS OF USE
HK40116651A (zh) 双官能基化合物及包含所述双官能基化合物的医药组合物及其用於治疗雄激素受体相关疾病的方法
WO2021033766A1 (ja) ビタミンｄ活性を有するリトコール酸誘導体
WO2025072637A1 (en) Oxygenated heterocyclic lsd-1 inhibitors and related methods of use
TW202521102A (zh) 免疫蛋白酶體選擇性抑制劑
JPH11100344A (ja) 新規な２、３−ジ置換シクロペンタノン誘導体及びその用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40117251

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination